Country: Canada
Language: English
Source: Health Canada
CALCIPOTRIOL
LEO PHARMA INC
D05AX02
CALCIPOTRIOL
50MCG
OINTMENT
CALCIPOTRIOL 50MCG
TOPICAL
60G/120G
Prescription
MISC. SKIN AND MUCOUS MEMBRANE AGENTS
Active ingredient group (AIG) number: 0123661001; AHFS:
MARKETED
1992-12-31
_Product Monograph Master Template _ _Template Date: September 2020 _ _DOVONEX® (calcipotriol) _ _Page 1 of 30_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR DOVONEX® calcipotriol Ointment, 50mcg/g, Topical ATC Code: D05AX02 Topical Non-Steroidal Antipsoriatic Agent LEO Pharma Inc. Thornhill, Ontario L3T 7W8 www.leo-pharma.ca. Date of Initial Authorization: Dec 31,1992 Date of Revision: December 13, 2021 Submission Control Number: 252165 ® Registered trademark of LEO Pharma A/S used under license by LEO Pharma Inc., Thornhill, L3T 7W8 _ _ _Product Monograph Master Template _ _Template Date: September 2020 _ _DOVONEX® (calcipotriol) _ _Page 2 of 30_ RECENT MAJOR LABEL CHANGES 1. INDICATIONS, 1.1 Pediatrics 12/2021 2. CONTRAINDICATIONS 12/2021 4. DOSAGE AND ADMINISTRATION, 3.1 Dosing considerations, 3.2 Recommended Dose and Dosage Adjustment, 3.3 Administration 12/2021 7. WARNINGS AND PRECAUTIONS, 6.1 Special Populations 12/2021 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.1 Dosing Considerations ............................................................... Read the complete document